Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir (OPAL)

This study has been completed.
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Radboud University Identifier:
First received: January 26, 2011
Last updated: July 23, 2012
Last verified: July 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2011
  Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)